Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2024 | OS sensitivity analysis of darolutamide, docetaxel and ADT in ARASENS

Neal Shore • 26 Jan 2024
GU Cancers 2024
Genitourinary Cancer Prostate Cancer Darolutamide Docetaxel
ARASENS

Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, comments on findings from the Phase II ARASENS study (NCT02799602) of darolutamide with androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). A post hoc sensitivity analysis of overall survival (OS) demonstrated that the investigational therapy significantly improved OS compared to placebo. Consistency in sensitivity analyses supports the triplet therapy as an effective and well-tolerated standard of care for early treatment intensification in mHSPC. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Neal Shore

EMBARK: long-term remissions with hormonal therapy in prostate cancer
1:44
EMBARK: long-term remissions with hormonal therapy in prostate cancer
Neal Shore • 26 Feb 2026
TulmiSTAR-02: tulmimetostat plus darolutamide or abiraterone in mHSPC
1:54
TulmiSTAR-02: tulmimetostat plus darolutamide or abiraterone in mHSPC
Neal Shore • 26 Feb 2026
177Lu-PSMA-617 after sipuleucel-T in mCRPC: PRECISION analysis
1:39
177Lu-PSMA-617 after sipuleucel-T in mCRPC: PRECISION analysis
Neal Shore • 26 Feb 2026
Assessing darolutamide and ADT safety vs other ARPIs in mCSPC
1:36
Assessing darolutamide and ADT safety vs other ARPIs in mCSPC
Neal Shore • 26 Feb 2026

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals